Literature DB >> 14506392

Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons.

Charles S Lieber1, Maria A Leo, Qi Cao, Chaoling Ren, Leonore M DeCarli.   

Abstract

UNLABELLED: GOAL/
BACKGROUND: Hepatoprotective effects of silymarin in patients with alcoholic liver disease are controversial. For strict control, this was assessed in non-human primates. STUDY Twelve baboons were fed alcohol with or without silymarin for 3 years with a nutritionally adequate diet.
RESULTS: Silymarin opposed the alcohol-induced oxidative stress (assessed by plasma 4-hydroxynonenal) and the rise in liver lipids and circulating ALT. Alcohol also increased hepatic collagen type I by 50% over the 3 years with a significant rise in mRNA for alpha1 (I) procollagen, both prevented by silymarin. There were corresponding morphologic changes: at 36 months, 2 of 6 animals fed alcohol had cirrhosis and 2 septal fibrosis, with perivenular fibrosis in 2, whereas with alcohol + silymarin, there was only 1 cirrhosis and 1 septal fibrosis, with perivenular fibrosis in 2, and virtually no lesions in the remaining 2.
CONCLUSIONS: Silymarin retards the development of alcohol-induced hepatic fibrosis in baboons, consistent with several positive clinical trials. The negative outcome observed in other trials possibly reflects poor compliance resulting in irregular or low silymarin intake. Thus, in view of the innocuity of silymarin, it might be advisable in future clinical studies to insure the controlled administration of sufficient amounts of silymarin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506392     DOI: 10.1097/00004836-200310000-00013

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  37 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs.

Authors:  Seung-Ki Chon; Nam-Soo Kim
Journal:  Parasitol Res       Date:  2005-09-09       Impact factor: 2.289

Review 3.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

4.  The protective effect of silymarin on the carbon tetrachloride (CCl4)-induced liver injury in common carp (Cyprinus carpio).

Authors:  Rui Jia; Liping Cao; Jinliang Du; Pao Xu; Galina Jeney; Guojun Yin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-02-22       Impact factor: 2.416

Review 5.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  Silymarin reduces profibrogenic cytokines and reverses hepatic fibrosis in chronic murine schistosomiasis.

Authors:  Hílton Antônio Mata-Santos; Fabianno Ferreira Dutra; Carolina Carneiro Rocha; Fabiana Gonçalves Lino; Fabiola Ramos Xavier; Leandro Andrade Chinalia; Bryan Hudson Hossy; Morgana Teixeira Lima Castelo-Branco; Anderson Junger Teodoro; Claudia N Paiva; Alexandre dos Santos Pyrrho
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

Review 7.  The use of selected nutrition supplements and complementary and alternative medicine in liver disease.

Authors:  A James Hanje; Brett Fortune; Ming Song; Daniell Hill; Craig McClain
Journal:  Nutr Clin Pract       Date:  2006-06       Impact factor: 3.080

8.  Effects and mechanisms of silibinin on human hepatoma cell lines.

Authors:  John-J Lah; Wei Cui; Ke-Qin Hu
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

9.  Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol.

Authors:  Lei Wang; Fu-Liang He; Fu-Quan Liu; Zhen-Dong Yue; Hong-Wei Zhao
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 10.  New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments.

Authors:  Charles S Lieber
Journal:  Curr Gastroenterol Rep       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.